U
Ulrich Beuers
Researcher at University of Amsterdam
Publications - 388
Citations - 22649
Ulrich Beuers is an academic researcher from University of Amsterdam. The author has contributed to research in topics: Primary sclerosing cholangitis & Cholestasis. The author has an hindex of 72, co-authored 351 publications receiving 18704 citations. Previous affiliations of Ulrich Beuers include Ludwig Maximilian University of Munich.
Papers
More filters
Journal Article
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
Ulrich Beuers,Kirsten Muri Boberg,Roger W. Chapman,Olivier Chazouillères,Pietro Invernizzi,David Jones,Frank Lammert,Albert Parés,Michael Trauner +8 more
TL;DR: The clinical care for patients with cholestatic liver diseases has advanced considerably during recent decades thanks to growing insight into pathophysiological mechanisms and remarkable methodological and technical developments in diagnostic procedures as well as therapeutic and preventive approaches.
Journal ArticleDOI
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
Vlad Ratziu,Vlad Ratziu,Stephen A. Harrison,Sven Francque,Pierre Bedossa,Philippe Lehert,Philippe Lehert,Lawrence Serfaty,Manuel Romero-Gómez,Jérôme Boursier,Manal F. Abdelmalek,Steve Caldwell,Joost P.H. Drenth,Quentin M. Anstee,Dean W. Hum,Rémy Hanf,A. Roudot,S. Megnien,Bart Staels,Arun J. Sanyal,Philippe Mathurin,J. Gournay,Eric Nguyen-Khac,V. de Ledinghen,Dominique Larrey,A. Tran,M. Bourliere,M. Maynard-Muet,Tarik Asselah,Jean Henrion,Frederik Nevens,David Cassiman,Albert Geerts,Christophe Moreno,Ulrich Beuers,Peter R. Galle,Ulrich Spengler,Elisabetta Bugianesi,Antonio Craxì,Mario Angelico,Silvia Fargion,M. Voiculescu,Liana Gheorghe,L. Preotescu,Juan Caballería,Raúl J. Andrade,Javier Crespo,J. L. Callera,Aftab Ala,Guruprasad P. Aithal,G. Abouda,Velimir A. Luketic,M. A. Huang,Stuart C. Gordon,Paul J. Pockros,Fred Poordad,N. Shores,M. W. Moehlen,Kiran Bambha,V. Clark,Sanjaya K. Satapathy,S. Parekh,R. K. Reddy,Muhammad Y. Sheikh,Gyongyi Szabo,John M. Vierling,T. Foster,Guillermo E. Umpierrez,C. Chang,Terry Box,J. Gallegos-Orozco +70 more
TL;DR: A post-hoc analysis of data from trial of patients with NASH showed that elafibranor (120 mg/d for 1 year) resolved NASH without fibrosis worsening, based on a modified definition, in the intention-to-treat analysis and in patients with moderate or severe NASH.
Journal ArticleDOI
EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis
Gideon M. Hirschfield,Ulrich Beuers,Christophe Corpechot,Pietro Invernizzi,David Jones,Marco Marzioni,Christoph Schramm +6 more
TL;DR: These clinical practice guidelines summarise the evidence for the importance of a structured, life-long and individualised, approach to the care of patients with PBC, providing a framework to help clinicians diagnose and effectively manage patients.
Journal ArticleDOI
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Frederik Nevens,Pietro Andreone,Giuseppe Mazzella,Simone I. Strasser,Christopher L. Bowlus,Pietro Invernizzi,J.P.H. Drenth,Paul J. Pockros,Jaroslaw Regula,Ulrich Beuers,Michael Trauner,David Jones,Annarosa Floreani,Simon Hohenester,Velimir A. Luketic,Mitchell L. Shiffman,K.J. van Erpecum,Victor Vargas,Catherine Vincent,Gideon M. Hirschfield,Hemant Shah,Bettina E. Hansen,Keith D. Lindor,Hanns-Ulrich Marschall,Kris V. Kowdley,R. Hooshmand-Rad,T. Marmon,S. Sheeron,R. Pencek,Leigh MacConell,Mark Pruzanski,David Shapiro +31 more
TL;DR: Obeticholic acid administered with ursodiol or as monotherapy for 12 months in patients with primary biliary cholangitis resulted in decreases from baseline in alkaline phosphatase and total bilirubin levels that differed significantly from the changes observed with placebo.
Journal ArticleDOI
Ursodeoxycholic acid in cholestatic liver disease: Mechanisms of action and therapeutic use revisited
Gustav Paumgartner,Ulrich Beuers +1 more
TL;DR: Experimental evidence suggests three major mechanisms of action of UDCA, which may improve serum liver chemistries, delay disease progression to severe fibrosis or cirrhosis, and may prolong transplant‐free survival in primary biliary Cirrhosis and primary sclerosing cholangitis.